Glyco Terminates Agreement with Magna in US to sell wound gel product

December 4, 2023-Glyco termianted irs agreement with Magna Pharmaceuticals, Inc. in full to sell Glyco's IPM Wound Gel Bio product in the US, as covered by Glyco FDA 510(k) clearnace K143527, Magna is to cease and desist from any further sales of Glyco's product in the US.